A Prospective,Multi-center,Cohort Trial: the Efficacy and Safety of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus(HBV)
Latest Information Update: 10 Aug 2021
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- 26 Jun 2021 Results (n=89) assessing efficacy and safety of tenofovir alafenamide for preventing mother-to-childtransmission of hepatitisB virus, presented at The International Liver Congress 2021.
- 23 Aug 2019 New trial record